Research Applications
Neuroprotection in stroke and TBI. Cardioprotection. Anti-inflammatory therapy. Tissue repair without erythropoiesis.
Mechanism of Action
Activates the tissue-protective EPOR/βcR receptor complex, engaging JAK2/STAT5, PI3K/Akt, and NF-κB anti-inflammatory signaling without activating the erythropoietic EPOR homodimer.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsResearch Studies
Non-Erythropoietic EPO Derivatives for Tissue Protection
Brines M, Cerami A.
Frequently Asked Questions
Epobis is a peptide derived from erythropoietin (EPO) that retains the tissue-protective and cytoprotective properties of EPO without stimulating erythropoiesis (red blood cell production). Like ARA 290, it targets the innate repair receptor (EPOR/βcR heterodimer) rather than the classical erythropoietic EPOR/EPOR homodimer. Preclinical research demonstrates neuroprotective, cardioprotective, and anti-inflammatory effects mediated through JAK2/STAT5 and PI3K/Akt survival signaling pathways. This approach separates EPO's beneficial tissue-protective effects from its potentially dangerous erythropoietic effects (thrombosis risk with elevated red blood cells).
Activates the tissue-protective EPOR/βcR receptor complex, engaging JAK2/STAT5, PI3K/Akt, and NF-κB anti-inflammatory signaling without activating the erythropoietic EPOR homodimer.
Neuroprotection in stroke and TBI. Cardioprotection. Anti-inflammatory therapy. Tissue repair without erythropoiesis.
